Fox Run Management, L.L.C. Bristol Myers Squibb CO Transaction History

Fox Run Management, L.L.C.

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$40.25 - $52.99 $749,012 - $986,090	18,609 New	18,609 $772,000
Q2 2023 Aug 11, 2023	BUY	$63.71 - $70.74 $1.33 Million - $1.47 Million	20,816 New	20,816 $1.33 Million
Q4 2022 Feb 07, 2023	BUY	$68.48 - $81.09 $1.02 Million - $1.21 Million	14,929 New	14,929 $1.07 Million
Q1 2022 May 10, 2022	SELL	$61.48 - $73.72 $305,432 - $366,240	-4,968 Closed	0 $0
Q4 2021 Feb 09, 2022	SELL	$53.63 - $62.52 $699,764 - $815,760	-13,048 Reduced 72.42%	4,968 $310,000
Q3 2021 Nov 15, 2021	BUY	$59.17 - $69.31 $852,698 - $998,826	14,411 Added 399.75%	18,016 $1.07 Million
Q2 2021 Aug 05, 2021	BUY	$61.91 - $67.42 $223,185 - $243,049	3,605 New	3,605 $241,000
Q4 2019 Feb 14, 2020	SELL	$49.21 - $64.19 $333,791 - $435,400	-6,783 Closed	0 $0
Q3 2019 Oct 15, 2019	BUY	$42.77 - $50.71 $290,108 - $343,965	6,783 New	6,783 $344,000
Q1 2019 Oct 17, 2019	SELL	$45.12 - $53.8 $203,852 - $243,068	-4,518 Closed	0 $0
Q4 2018 Jan 15, 2019	SELL	$48.76 - $63.23 $263,742 - $342,011	-5,409 Reduced 54.49%	4,518 $235,000
Q3 2018 Oct 05, 2018	BUY	$55.19 - $62.25 $50,554 - $57,021	916 Added 10.17%	9,927 $616,000
Q2 2018 Jul 17, 2018	SELL	$50.53 - $62.98 $541,732 - $675,208	-10,721 Reduced 54.33%	9,011 $499,000
Q1 2018 Apr 17, 2018	BUY	$59.92 - $68.98 $1.18 Million - $1.36 Million	19,732 New	19,732 $1.25 Million
Q4 2017 Jan 18, 2018	SELL	$59.94 - $65.35 $1 Million - $1.09 Million	-16,700 Closed	0 $0
Q3 2017 Oct 23, 2017	BUY	$55.23 - $63.74 $922,341 - $1.06 Million	16,700	16,700 $1.06 Million

2,533

1.47B

31.6M

35M

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $124B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

Get notified when there are updates to the investment portfolio of Fox Run Management, L.L.C., based on Form 13F filings with the SEC.

Stay updated on Fox Run Management, L.L.C. with notifications on news.